Sentence examples for mutants to block from inspiring English sources

The first approach used Met to Leu mutants to block site-specific Met oxidation.

Experiments comparing the ability of VP35 mutants to block IFN responses demonstrated that the VP35 amino-terminus, which retains the putative coiled-coil motif, was unable to inhibit IFN responses, whereas the VP35 carboxy-terminus weakly inhibited the activation of IFN responses.

First, we used the expression of dominant-negative mutants to block endogenous protein functions and second, we specifically depleted key functional molecules within these pathways by siRNA.

We screened all of our sequences for evidence of failure of the inverted repeat mutants to block further rounds of recombination.

Indeed, when the authors introduced mutations abrogating Fc receptor binding (i.e., LALA mutations) within each of the three monoclonal antibodies and used the mutants to block ADCC triggered by whole plasma, they observed robust inhibition by the LALA versions of the two antibodies specific for CD4-induced epitopes and no inhibition by the LALA version of the anti-V3 monoclonal antibody.

To examine the potential for preventing cleavage at the 38/42 sites, we produced further Fwt heterodimer mutants designed to block cleavage at one or more of these sites, and at a third putative alternative 38/42 site unique to MSP1-F.

These interactions may be sufficient for both wild-type and mutant HARP to block the phosphorylation of RPA2.

As suggested by the reviewers, we have now included experiments that compare the ability of wild type and mutant (N102S) UBIAD1 to block degradation of full-length reductase.

A more realistic strategy is to study the potential of systemic administration of non-HS-binding mutant chemokines to block site-specific recruitment of immune cells induced by local administration of wild-type chemokines.

These results suggest that mutant parasites continue under the tachyzoite cell cycle in bradyzoite growth conditions and the genes disrupted in the mutants are likely to block bradyzoite differentiation upstream of the decision to change the cell cycle, i.e. the signal that leads to the change from the tachyzoite to bradyzoite cycle maybe blocked in these mutants.

Indeed, the PPI-deficient CypB mutants are able to block the proliferation of breast cancer cell lines at concentrations two to three orders of magnitude less than other described mutant PRL antagonists [ 45].